01—Abstract
Summary
Summary of the 10-K filed February 14, 2020. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' 2019 10-K shows a year of strong top-line growth and margin expansion.
Revenue rose 8.8% reported (10.3% organic) to $2.41 billiona, driven by recurring CAG Diagnostics revenue (76% of consolidated revenue), particularly IDEXX VetLab consumables (+12.3%) and reference laboratory services (+10.1%). Gross margin expanded 60 basis points to 56.7%, and operating income grew 12.5% to $552.8 million (23.0% margin). Diluted EPS rose to $4.89 from $4.26, though 2019 results included a roughly $12.2 million after-tax charge tied to the CEO transition.
Cash generation remained solid, with operating cash flow of $459.2 millionb against capital expenditures of $155.0 million. The company repurchased $303.8 million of stock (1.22 million shares) and expanded its share repurchase authorization by 5.0 million shares in February 2020, to a total of 73 million. Leverage is moderate: gross debt to Adjusted EBITDA was 1.45x and net debt to Adjusted EBITDA was 1.32x, well inside the 3.5x covenant.
Total stockholders' equity turned positive at $177.8 millionc after several years of deficits, reflecting accumulated earnings and buybacks. Key watch items include a leadership transition (Jay Mazelsky became CEO in October 2019), a $850 million credit facility that matures in December 2020 and is classified as current, a 2020 capex plan of $140 to $155 million, and continued exposure to currency, since 38% of revenue is international. Management also flagged competitive pressure, consolidation among corporate veterinary hospital owners, and reliance on sole-source suppliers such as Ortho for chemistry slides.
02—Key points
Key Highlights
- Revenue grew 8.8% reported (10.3% organic) to $2,406.9 million, with U.S. revenue up 10.1% and international up 6.6%.
- Recurring diagnostic revenue reached roughly 76% of consolidated revenue, led by IDEXX VetLab consumables (+12.3%) and reference laboratory services (+10.1%).
- Gross margin expanded 60 basis points to 56.7%, and operating income rose 12.5% to $552.8 million, a 23.0% operating margin.
- Diluted EPS increased to $4.89 from $4.26, though 2019 included a roughly $12.2 million after-tax charge from the CEO transition.
- Operating cash flow was $459.2 million, and free cash flow after $155.0 million of capex was about $304 million.
- The company repurchased $303.8 million of stock in 2019 and raised its authorization by 5.0 million shares to 73 million in February 2020.
- Leverage is modest at 1.45x gross debt to Adjusted EBITDA. The $850 million credit facility matures December 4, 2020, and is classified as a current liability.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2019, IDEXX Laboratories kept $0.18.
- Revenue$2.41B100.0%
- Cost of revenue−$1.04B43.3%
- Gross profit$1.37B56.7%
- Operating costs−$812.7M33.8%
- Operating income$552.8M23.0%
- Interest, other & tax−$125.1M5.2%
- Net income$427.8M17.8%
Where FY2019 revenue went
$2.41B- Cost of revenue: $1.04B, 43% of revenue
- Other operating costs: $679.5M, 28% of revenue
- Net income: $427.8M, 18% of revenue
- R&D: $133.2M, 5.5% of revenue
- Interest, other & tax: $125.1M, 5.2% of revenue
Kept 18% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2019filed February 14, 2020Financial Statements
FY2019 against FY2018
| Line item | FY2019FY2018 | Change |
|---|---|---|
| Revenue | $2.41B$2.21B | +8.8% |
| Cost of Revenue | $1.04B$971.70M | +7.2% |
| Gross Profit | $1.37B$1.24B | +10.0% |
| R&D Expenses | $133.19M$117.86M | +13.0% |
| Operating Income | $552.85M$491.33M | +12.5% |
| Interest Expense | $31.05M$34.74M | −10.6% |
| Net Income | $427.79M$377.03M | +13.5% |
| EPS (Basic) | $4.97$4.34 | +14.5% |
| EPS (Diluted) | $4.89$4.26 | +14.8% |
| Shares Outstanding (Basic) | 86.11M86.86M | −0.9% |
| Shares Outstanding (Diluted) | 87.54M88.47M | −1.0% |
05—Questions
Frequently Asked Questions
Why did IDEXX's operating margin and EPS improve in 2019?
Growth in high-margin recurring revenue, mainly VetLab consumables and reference laboratory testing, drove volume leverage and mix benefits. Gross margin rose 60 basis points, and operating expenses grew more slowly than revenue (8.3% versus 8.8%). Price increases and favorable currency effects on gross profit also contributed. Net income grew about 13.5% to $427.7 million, and diluted EPS rose to $4.89 from $4.26, helped by a lower share count from buybacks.
How much risk does the credit facility maturity in December 2020 pose?
The $850 million revolver had $288.8 million drawn at year-end 2019 and $559.8 million of availability. It matures December 4, 2020, and its borrowings are classified as current, which pushed working capital negative (-$45.7 million). Management believes cash, operating cash flow, and committed availability are sufficient for the next twelve months. Refinancing or an extension will be a near-term item to monitor. The company also has $700 million of senior notes with staggered maturities from 2021 to 2029, and it noted that its ability to borrow at similar rates is likely.
What are the main currency and international exposures?
About 38% of 2019 revenue came from outside the U.S. Management estimates that a 1% stronger U.S. dollar would reduce 2020 revenue by roughly $9 million and operating income by about $5 million. At current exchange rates, a stronger dollar is expected to cut 2020 revenue by about $11 million, operating profit by $10 million, and EPS by $0.09, including hedging effects. The company hedges about 85% of its intercompany exposure in major currencies, but emerging-market and service exposures are largely unhedged.
What operational or competitive risks should investors weigh?
Key risks include sole- and single-source suppliers, most notably Ortho Clinical Diagnostics for VetTest and Catalyst chemistry slides, under agreements that run to December 2028. Consolidation among corporate veterinary hospital owners such as Mars (Banfield and VCA) and buying consortiums could shift purchasing and pressure pricing. Larger, well-funded competitors are also a factor. Other risks include changes in testing patterns (for example, vaccines or disease eradication), the African swine fever outbreak affecting livestock testing in China, and the cybersecurity and data privacy obligations under GDPR and the CCPA.
What did the leadership transition and 2020 outlook look like?
Jonathan Ayers stepped down as Chairman and CEO in 2019. Jay Mazelsky, a long-time executive, was appointed CEO in October 2019, and Lawrence Kingsley became independent non-executive Chairman in November 2019. The transition cost about $13.4 million in operating charges, and the company said the total net income impact was about $12.2 million. For 2020, the company guided to a capital expenditure plan of $140 to $155 million, including expansion of its Westbrook, Maine headquarters and relocation of its German reference laboratory. It also expects share-based compensation to lower the 2020 effective tax rate by about 1.5 points.
06—Continue